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Abstract 
 Found in all eukaryotic organisms, the Mediator complex is an essential component of the 
transcription machinery and acts as a molecular bridge between activators and other general 
transcription factors. The transcription factor p53 is a potent tumor suppressor and acts as a master 
controller of the cell cycle and programmed cell death. Binding of p53 to Mediator induces 
conformational shifts that activate RNA polymerase II transcription. In the wild type form, p53 aides in 
inhibiting growth of cancerous cells, but this is not the effect seen in mutant p53. Two breast cancer cell 
lines, MCF7 and MDA-MB-231 are clinically distinct with varying molecular backgrounds as the first 
expresses wild type p53 and the latter expresses hyperactive, mutant p53. In order to determine which 
transcription regulatory factors are common and different between the two cell lines, purifications were 
carried out to isolate the Mediator complex from each of these two cell types. Further, to analyze the 
p53 network and p53-Mediator interactions, a different set of purifications were completed using 
nuclear extracts from both breast cancer cell types. Mass Spectrometry analysis of these samples 
identified proteins that are similar and different in the two distinct breast cancer cell lines. In future 
work, these differences will be explored to determine whether they might contribute to clinical 
differences, which include metastatic growth and drug resistance.  
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Figure 1. Front and side views of Mediator (blue mesh) interacting with the bound pol II (red 
ribbon structure) and the additional transcription initiation factors. (Bernecky, 2011) 
 
Table 1. The transcription 
initiation machinery that 
composes the PEC (Taatjes, 2010). 
 
Introduction 
 Transcription propagates the first step of the central dogma of molecular biology: DNA 
(deoxyribonucleic acid) to RNA (ribonucleic acid) to protein. The transcriptional machinery includes RNA 
polymerase II (pol II) which transcribes an RNA transcript from the DNA template. This RNA transcript is 
then edited and used to guide the synthesis of specific proteins that are needed for various cell 
processes. In addition to pol II, many other general transcription factors are required in transcriptional 
events. Included in these factors is the Mediator complex, an essential component in the composition of 
the preinitiation complex (PIC) at the transcription start site. The pre-elongation complex (PEC) is a more 
broad term to include genes that are regulated post recruitment of 
pol II where minimal to no initiation may have occurred (Taatjes, 
2010). PIC and PEC are equivalent terms and PEC will be used for the 
remainder of this thesis. The composition of the PEC is shown in 
Table 1.  
 Contained within a gene are promoter regions of DNA to 
which activators and repressors can bind to either up or down 
regulate transcription. Activators are DNA-binding transcription 
factors that regulate the interactions between Mediator and pol II. Specific activators are recruited to 
different coding regions, depending on the gene that is being transcribed.  One such activator is p53, a 
tumor suppressor protein. Often referred to as the “master regulator,” p53 oversees the cell cycle and 
plays an essential role 
in abating the growth 
of cancerous cells.  
I. The Mediator 
Complex 
 Found in both 
yeast and humans, 
Mediator is a large, 
1.2MDa complex that 
consists of 26 subunits. Mediator functions at all pol II promoters in yeast and therefore, is thought to 
function at all human pol II promoters as well. It acts in part by binding to the C-terminal domain (CTD) 
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Figure 2. Mediator’s associations with both activators and the pol II transcription 
machinery allow it to act as a bridge between the different factors 
(http://www.colorado.edu/chemistry/taatjeslab/background.htm). 
 
Figure 3. Different conformational states are 
induced in Mediator in the presence of 
different activators, leading to gene specific 
activation (Ebmeier and Taatjes, 2010). 
of pol II. Due to its necessity in transcription, Mediator can thus be considered a general transcription 
factor.  As a target of a 
broad spectrum of 
activators, Mediator 
functions as an essential 
co-activator during 
transcriptional activities 
(Kornberg, 2005). This is 
greatly due to Mediator’s 
size and shape, enabling a 
large surface area to be utilized for different, simultaneous protein-protein interactions. It is known that 
these interactions include the physical connection between mediator and many factors that comprise 
the PEC, including TFIIB, TFIID, TFIIE, TFIIH and most importantly pol II. While the specific structure of 
the entire PEC has yet to be elucidated, the cryo-EM structure of Mediator-pol II-TFIIF allowed a model 
of the human PEC to be proposed (Figure 1). This model suggests that Mediator acts as a fundamental 
scaffold to which activators and general transcription factors can bind, creating a molecular bridge 
between activators and pol II transcription machinery (Figure 2). The extensive composition of Mediator 
gives it the ability to integrate various signals received from 
other co-activators in addition to repressors (Malik, 2005). 
 The binding of activators to Mediator initiates a 
conformational change in Mediator, allowing for the 
activation of specific genes, depending on the activator that is 
present. The structure of Mediator is closely related to its 
functional capabilities (Figure 3), leading to the concept that 
activators themselves control the function of Mediator by 
changing its structural state, which can affect downstream 
interactions of Mediator with additional co-factors (Ebmeier 
and Taatjes, 2010). Interestingly, activator binding appears to 
be needed in order for Mediator-cofactor interactions to take 
place. An activator needs to be present in order to induce a 
structural shift in Mediator. This shift only takes place when 
p53 
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Figure 4. Viewed from the bottom, different Mediator structures bound to 
different activating. The arrows point towards the pol II binding pocket. 
The inactive conformation in which Mediator is not bound to an activator, 
lacks this pocket (Meyer, 2010). 
 
Figure 5. Protein map displaying the different domains of p53. The numbers 
represent amino acids (Anzola, 2003). 
Mediator is in close proximity with the promoter, because activators bind DNA at the promoter. Figure 3 
represents this model of activator control with two different activators: SREBP-1a and VP16. Different 
conformations of Mediator have a higher affinity for different co-regulating factors, leading to direct 
communication with the transcription 
machinery and activation of specific 
genes. Similar events take place in the 
presence of p53. Mediator takes on 
different conformations depending on 
if it is in the active form or not and 
what activators are presently bound 
to the complex (Figure 4). 
 All activated pol II 
transcription requires the presence of 
Mediator (Holstege, 1998). Gene 
specific activation requires the 
presence of distinct activators that 
interact with Mediator in such a way as to induce unique, conformational shifts. This suggests that by 
manipulating activator-Mediator interactions, gene expression can be managed. This implication reveals 
a store of possibilities relating to human health. Specifically, gaining control over the functions of 
diseased and cancerous cells in the body and determining their fate.  
II. Tumor Suppressor p53 
 The protein p53 is a transcription factor that regulates the cell cycle at the G1 stage and helps 
control aging in mammals. In its full length form, p53 is 393 amino acids long and binds DNA as a 
tetramer (Figure 5). Two different subunits of the Mediator complex are bound by different regions of 
p53 (Meyer, 2010). The 
activation domain at the N-
terminal of p53 (p53AD) 
operates with the Med17 
subunit, while the C-
terminal domain of p53 
(p53CTD) interacts with 
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Figure 7. Summarized p53 pathway. 
 
Figure 6.  The active and inactive conformations of Mediator, depending on which region of 
transcription factor p53 the complex is bound to. The pocket indicates the pol II binding 
domain, and is not present in the p53CTD-Mediator structure (Meyer, 2010). 
Med1. Upon binding of p53AD to Mediator, the complex undergoes structural shifts that apparently 
induce previously 
stalled pol II 
machinery to initiate 
elongation of a 
transcript (Figure 4). 
This is interesting to 
note, because certain 
genes targeted by 
p53 have promoters 
with pol II already 
preloaded but are 
inactive. 
Consequently, the 
conformational changes that Mediator undergoes after the binding of p53 are needed to stimulate the 
stalled pol II and to also oversee the post-recruitment events that take place in the activation of a gene.  
Furthermore, two p53 regulated genes, p21 and HDM2, do not require the presence of p53 to compile 
the transcription initiation machinery (PEC), and Mediator unbound by p53 is not sufficient to induce 
activation of the stalled pol II (Knuesel, 2011). Specifically, p53AD-Mediator interaction and its 
associated structural change is vital for activating stalled pol II at p21 and HDM2, whereas p53CTD-
Mediator binding is unable to initiate transcription due to its inability to appropriately activate pol II 
(Figure 6). Genes responsive to p53 are highly dependent on the p53AD-Med17 interaction, thus 
alluding to numerous possibilities of manipulating p53 
activity in cancer cells (Knuesel, 2011). 
 When regulating cancerous cells, p53 is considered 
one of the most important tumor suppressors and is known 
as a “master executioner,” due to its ability to block 
angiogenesis, arrest the cell cycle and/or trigger 
programmed cell death in response to DNA damage, 
hyperactivation of oncogenes and other cellular stresses 
(Figure 7). In cancer, p53 is the most commonly mutated tumor suppressor gene. The most prevalent 
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mutation is a missense mutation, which falls in the DNA-binding domain of the protein, suggesting that 
normal DNA binding activity is vital for maintaining tumor suppressor activity. Furthermore, in order for 
DNA binding to occur, all four p53 monomers are required. One mutant monomer can inactivate the 
entire tetramer complex. Mutant p53 in a non-cancerous situation can be equally as detrimental. The 
protein’s function is essential in sustaining a healthy environment by promoting the proliferation of 
healthy cells and impeding the growth of detrimental ones.  
III. Breast Cancer Lines: MCF7 and MDA-MB-231 
 Both of these cancers are adenocarcinomas, cancers of the breast epithelium tissue that 
originated in the mammary gland. The MCF7 breast cancer line was derived from an in situ carcinoma, 
meaning that the cancerous cells had not yet invaded surrounding tissues. It is hormone responsive in 
the sense that it expresses estrogen and progesterone receptors. Estrogen is a known tumor promoter. 
Mammary gland epithelium expresses estrogen receptor and the presence of estrogen stimulates the 
non-specific proliferation of cells. The advantage of a cancer being sensitive to hormones is that if the 
hormone receptor, in this case the estrogen receptor is blocked, then cell growth and cancer can be 
inhibited (Alkhalaf, 2003). On the other hand, the MDA-MB-231 breast cancer line was derived from a 
metastatic carcinoma and is not hormone sensitive; so, blocking the estrogen receptor in these cells will 
do nothing to inhibit the cancer. This line also expresses epidermal growth factor (EGF), an oncogene.  
 Clinically, the cancer of the MDA-MB-231 cell line is harder to treat (Sorlie, 2009). Relative to 
MCF7 cells, MDA-MB-231 cells grow faster and are more resistant to drug therapies. For instance, 
resveratrol is an antimicrobial substance that is naturally produced by plants when exposed to 
pathogens. It has gained attention due to its potential chemopreventative nature in fighting human 
cancers. While resveratrol hindered cell growth and activity in both MCF7 and MDA-MB-231 cells, only 
in the MCF7 cells was it able to induce apoptosis, the desired fate of cancerous cells (Pozo-Guisado, 
2002). Furthermore, Akt is a downstream component of the PI3K intracellular signaling cascade, a key 
pathway in cellular survival. When Akt inhibitors are used in conjunction with the drug doxorubicin, the 
drug’s anti-cancer effects are enhanced. MDA-MB-231 cells required Akt inhibitors in order for the 
growth inhibitory effects of doxorubicin to be maximized. On the other hand, the same level of growth 
inhibition is seen in MCF7 cells with use of solely Akt inhibitors, which did not augment the effects of 
doxorubicin (Wang, 2009). Noticeably, less aggressive methods are necessary when treating MCF7 cells 
than when treating MDA-MB-231 cells.  
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Figure 8. p53 protein expression 
levels in MCF7 and MDA-MB-231 
cells. Same actin levels control for 
loading (Hui, 2006). 
 These MCF7 and MDA-MB-231 cell lines differ further in the 
p53 that they express. The MCF7 cells have wild-type p53, whereas 
the MDA-MB-231 cells have mutant p53 due to an arginine to lysine 
mutation at position 280 (Gurtner, 2010). In human cancers, when 
p53 is mutant, it is common for the mutant protein to be more stable 
than the wild-type one and therefore, is present at greater levels 
(Hupp, 2000). This appears to be the case when comparing p53 
expression in MCF7 and MDA-MB-231 cells (Figure 8). Mutant p53 does not retain the tumor 
suppressing abilities of the wild-type.  In fact, mutant p53 often exhibits oncogenic characteristics. For 
example, phospholipase D (PLD) aids in the survival of cancer cells. In MDA-MB-231 cells, PLD levels are 
increased in comparison to MCF7 cells, and their elevated activity is required to sustain the mutant p53 
and their over expression (Hui, 2006). This is contrary to the MCF7 cells, where PLD activity actually 
inhibits wild-type p53. The clinical and molecular differences characteristic to each breast cancer will 
allow for significant comparison of Mediator and p53 interactions between MCF7 and MDA-MB-231 
cells.  
IV. Hypothesis 
 Both MCF7 and MDA-MB-231 cell lines have transcriptionally active p53. However, MDA-MB-
231 cells have a p53 gain-of-function, hyperactive mutation, whereas MCF7 expresses wild type p53. 
Due to the pivotal role both wild type and mutant p53 play in cancer, it is essential to identify the factors 
that control p53’s activity. The clinical features distinct to each breast cancer cell line are evidence of 
their dramatically different gene expression profiles (Kao, 2009). The implication follows that the 
identities and levels of p53 co-regulatory factors will also be very different in each cell type. Past studies 
have argued that different cancers possess different p53 activities, leading to different downstream 
responses depending on the cell type (Yu, 1999).  
 For instance, CXCR4 is a chemokine receptor that is likely to be involved in the motility and 
metastasis of breast cancer cells. Wild type p53 expressed in MCF7 cells repress the activity of CXCR4, 
while the cancer specific p53 mutation of MDA-MB-231 cells fails to repress CXCR4 expression (Mehta, 
2007). A similar hypothesis is that the subunit composition of Mediator may vary from one cell type to 
the other. Due to previous research done on the interactions between p53 and Mediator, it can be 
presumed that since MCF7 and MDA-MB-231 cells have different p53 networks, the p53-Mediator 
relationships between the two will also differ (Meyer, 2010). To determine these differences and to 
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Figure 9. Visual representation of potential factors specific to either p53 or 
 p53-Mediator and factors that may differ between each breast cancer cell line. 
identify differences expected in the p53 network in each cell type, a comprehensive and unbiased 
approach will be taken to identify Mediator, p53 network and p53-Mediator complexes in both breast 
cancers, using Mass Spectrometry. By elucidating differences between the two cell types, distinct 
aspects of either the p53 pathway or Mediator can be targeted to change the clinical features of MCF7 
and MDA-MB-231 and make treatment of these cancers more manageable.  
Results 
I. Project Overview 
 In order to analyze Mediator, nuclear extract needs to be generated. This was done by culturing 
the breast cancer cells on tissue culture plates and then isolating the nuclei from these cells. Purification 
steps carried out on the nuclei resulted in the final form of the nuclear extract (see experimental 
procedures). These extract samples were used in the prospective experiments. 
 To isolate Mediator in MCF7 or MDA-MB-231 cells, immunoprecipitations (IP) were carried out 
on the nuclear extracts using an antibody that binds the MED1 subunit of Mediator. Mass spectrometry 
(MS) analysis of these MED1 IP 
samples will define the exact 
Mediator subunit composition 
in each cell type. In addition, 
MS analysis might identify 
cofactors that interact with 
Mediator. Next, to identify the 
cofactors that specifically 
interact with Mediator when 
bound to p53, p53-Mediator 
samples were isolated using a 
GST-p53 affinity column. 
Comparative MS analysis of p53-Mediator and Mediator IP samples allows for identification of cofactors 
that selectively bind to the p53-Mediator complex. 
 Additionally, other co-regulators may be present in the p53 network that do not interact with 
Mediator, but rather directly with p53 (Figure 9). Therefore, p53-Mediator complexes need to be 
separated from factors bound to p53 directly. Since Mediator is so large (1.2-1.8MDa), this separation is 
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     Nuclear Extract 
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    wash 
 
Figure 10. (A) Purification scheme showing how nuclear extract material was prepared for IP. SDS-PAGE and silver stain analysis of 
MED1 IP with MCF7 (B) and MDA-MB-231 (C) cells. Both cell types exhibit the distinct MED1 subunit band at 220kDa.  
possible by carrying out glycerol gradient sedimentations. An advantage of this protocol is that it allows 
for comprehensive analysis of potential changes in both the p53 network (i.e. factors bound directly to 
p53) and the p53-Mediator complex in each clinically distinct breast cancer cell line. Each cell type 
generated two sets of samples: the early fractions of the glycerol gradient that were comprised of p53 
network factors, and the late fractions that included the larger p53-Mediator network.  
II. Immunoprecipitation of the Mediator Complex 
 The technique of immunoprecipitation employs the use of an antibody to precipitate out a 
specific protein or protein complex in solution (see experimental procedures). TRAP220/MED1 antibody 
was used to isolate Mediator from the MCF7 and MDA-MB-231 nuclear extracts. Incubation of the 
antibody with the extract allows isolation of Mediator, because the antibody recognizes and binds 
specifically to the MED1 subunit of Mediator. Carrying out high salt washes on the immobilized antibody 
resin removes extraneous material and allows for isolation of relatively pure Mediator samples. The use 
of the detergent sarkosyl as the eluting agent removes Mediator from the antibody resin by denaturing 
all proteins bound to the resin (Figure 10A). As a control, samples of the A/G resin beads were loaded 
alongside a sample of the eluted material. Proteins bound and eluted from the resin were visualized 
with silver staining.  
 The use of the same antibody to precipitate out Mediator in each cell line allows for side by side 
analysis of the two cell samples. Both display the expected Mediator polypeptide bands, as shown in the 
silver-stained gels in Figures 10B and 10C. Twelve different samples of MCF7 and nine different samples 
of MDA-MB-231 extract were used to carry out twelve and nine separate IPs, respectively. This volume 
of material is need for reliable protein identification using MS. 
A    B    C 
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III. Isolation of p53-Mediator and other p53-associated factors 
 To observe p53-Mediator interactions in each cell line (MCF7 or MDA-MB-231), GST-p53 was 
first recombinantly expressed from E. coli. The activation domain of p53 (residues 1-70) was used 
instead of the full-length p53 protein (393 residues). This minimizes isolation of contaminants and 
Figure 11. (A) Separation scheme 
diagramming how nuclear extract samples 
were prepared for glycerol gradient 
purifications. (B) Visualization of MCF7 
gradient. (C) Visualization of MDA-MB-231 
gradient.  
 
A   B 
  C 
(p53 Network) 
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ensures that coregulatory factors important for transcription, including Mediator, are isolated. The GST-
p53 activation domain was purified and immobilized onto GSH-sepharose beads, which were then used 
to carry out pull downs from nuclear extracts derived from each cell type. The eluted p53-bound 
material was then loaded onto a 15-40% glycerol gradient (Figure 11A).  Glycerol gradient centrifugation 
is another means of protein purification. In centrifuge tubes, a linear gradient is created with the highest 
concentration of glycerol (40%) at the bottom of the tube and lowest concentration (15%) at the top. 
When spun at high speeds (50,000RPM), the larger protein complexes (e.g. Mediator) migrate towards 
the bottom of the tube faster than the smaller protein complexes or individual polypeptides. By taking 
100µL fractions, different p53 and p53-Mediator complexes are sequestered in each fraction. SDS-PAGE 
and silver stain analysis of these fractions allows for visualization of the distinct protein subunits present 
in the different fractions. Twelve different MCF7 samples and ten different MDA-MB-231 samples were 
used to yield twelve and ten different gradients. This volume of material is necessary for comprehensive 
MS analysis and protein identification. 
 The early fractions of the glycerol gradients, highlighted by the white boxed lanes in Figures 11B 
and 11C, are representative of the p53 network in each individual breast cancer. These samples 
represent individual proteins or smaller complexes bound to p53. This typically includes fractions 5-8 of 
each gradient. Since MCF7 and MDA-MB-231 cells express different sets of regulatory cofactors that 
affect p53 activity, the lanes representing these early fractions may have different band profiles 
between the two cell lines. Planned MS analysis of these fractions will identify these cofactors. The late 
fractions of interest, emphasized by the red boxed regions in Figures 11B and 11C, illustrate p53-
Mediator complexes. Most commonly, Mediator appears in fractions 13-17, depending on analysis of 
each individual sample.  These fractions exhibit the typical Mediator protein profile, as evidenced by the 
individual bands representing the different subunits that comprise the complex (Figures 11B and 11C). 
The differences in p53-Mediator interactions between MCF7 and MDA-MB-231 cells can begin to be 
assessed by examining the bands that differ between the two in the late fraction regions. However, to 
most reliably identify similarities and differences within p53-Mediator or the p53 network in each cell 
type, mass spectrometry will be used. 
 
 
 
 
 C 
   
  A 
   B 
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 Figure 12. Sample preparation for mass spectrometry analysis (Cravatt, 2007). 
 
MDA-MB-231 MCF7 
  unique peptides: 4424    unique proteins: 1431   
IP Samples 9 12 
Peptides 12051 6721 
Proteins 1181 712 
Mediator Spectral Counts 460 429 
 
Table 2. Number of peptides and proteins identified in each breast cancer 
cell line via MS analysis.  
 
IV. Mass Spectrometry 
 Use of MS allows for comprehensive characterization and analysis of the protein components 
that compose 
the different 
samples: 
MED1 IP, 
early fractions 
(p53 network) 
and late 
fractions 
(p53-
Mediator) of the glycerol gradients. Furthermore, comparison of the MS data of the breast cancer cell 
lines will elucidate factors that differ between the two. All samples were prepared equally with minimal 
variance in the conditions. They were first digested with trypsin to generate a peptide mixture that is 
able to be analyzed by liquid-chromatography-tandem mass spectrometry (LC-MS/MS).  The trypsinized 
peptide mixture is first separated by the liquid chromatography system, allowing the mass spectrometer 
to measure the mass to charge ratio of each peptide and then determine the individual molecular 
masses of the peptides (Figure 12).  Searching the results in a human protein database identifies the 
peptides present in the original sample. Mass spectrometry sample preparation and data generation 
was carried out by Chris Ebmeier of the Taatjes Lab.  
 The MED1 IP samples generated from MCF7 and MDA-MB-231 were subject to MS analysis. The 
results were searched against the human protein database ipi_Human_v3_75. Each peptide that is 
identified is given a spectral count of one. A 1% false discovery rate was used, meaning that each 
peptide has a 99% probability of being correctly identified (Old, 2005). The results obtained are 
qualitative and not normalized based on spectral counts. Between the two samples a total of 4424 
unique peptides and 1431 
unique proteins were found. 
Numbers of peptides and 
proteins specifically found in 
each breast cancer cell line 
15 
 
sample are listed in Table 2. More peptides and proteins are identified in the MDA-MB-231 cell sample 
than the MCF7 sample. 
  All of the Mediator subunits were identified (Table 3). The MDA-MB-231 sample produced 460 
total Mediator spectral counts while the MCF7 samples produced 429. Data was then further separated 
by factors that were exclusively found in the MDA-MB-231 cell line and the MCF7 line (Appendices A and 
B). This allows for significant comparison and analysis of proteins and potential gene pathways that are 
similar and different between the two cell lines.  
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Table 3. Mediator subunits identified by mass 
spectrometry in MED1 IP purified MCF7 and MDA-MB-
231 samples.  
Discussion 
 Evidence compiled from the MED1 
immunoprecipitation data suggests that both MCF7 
and MDA-MB-231 cells express similar Mediator 
complexes. This was as expected, because all 
eukaryotes express Mediator as a part of the 
transcription machinery. As figures 10B and 10C 
show, both breast cancer cell lines possess similar 
peptide patterns resulting from MED1 IP 
purification. However, the silver stained gels do not 
quantify the amount of each Mediator subunit that 
is present. Previous data has shown that among 
different breast cancer lines, different Mediator 
subunits may be expressed at different levels (Kao, 
2009). Consistency in Mediator subunits across the 
various cell types is not guaranteed.  
 MS data presented in Table 3 reveals that 
MCF7 cells and MDA-MB-231 cells share similar 
Mediator subunit profiles. Although analysis is 
qualitative and not quantitative, and spectral 
counts differ between the two cancer cell types, 
each line expresses nearly all of the Mediator 
subunits (Table 3). These results are consistent with 
expectations, because Mediator functions at all pol 
II promoters.  
 Factors found exclusively in each cell line 
with a spectral count of 4 and above were 
separately searched against the HEFalMP database of genes that are relevant to pol II transcription in 
breast cancer. HEFalMP utilizes hundreds of publicly available genome databases to generate functional 
maps of the human genomes. When a list of genes, cellular processes and diseases are specified, the site 
is able to make educated predictions on possible gene pathways (Huttenhower, 2009). The relationship 
Gene 
MDA-MB-231 
Spectral Counts 
MCF7 
Spectral Counts 
MW 
(Da) 
MED1 4 2 168478 
MED10 6 6 15688 
MED11 0 3 13129 
MED12 60 71 243081 
MED12L 0 2 240032 
MED13 53 35 239318 
MED13L 19 19 242602 
MED14 24 28 160607 
MED15 12 28 86753 
MED16 24 8 96793 
MED17 32 24 72876 
MED18 3 0 24453 
MED19 4 2 26273 
MED20 13 10 23222 
MED21 5 10 15564 
MED22 1 6 16480 
MED23 26 46 156194 
MED24 59 45 110305 
MED25 13 4 84389 
MED26 10 2 65446 
MED27 8 8 35432 
MED28 0 3 19520 
MED29 1 7 23473 
MED30 7 5 20277 
MED31 3 3 15805 
MED4 28 14 29745 
MED6 5 1 29298 
MED7 11 10 27245 
MED8 6 10 32819 
MED9 7 2 16403 
CCNC 4 4 33243 
CDC2L6 12 11 56802 
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Gene Name 
MDA-MB-231 
p-value 
MCF7 
p-value 
PHB prohibitin 0 - 
TSG101 tumor susceptibility gene 101 0 0 
PPM1D 
protein phosphatase 1D 
 magnesium-dependent 0 3.34E-06 
PIK3CA 
phosphoinositide 3-kinase,  
catalytic 0 2.00E-05 
BRCA1 breast cancer 1, early onset 0 - 
BARD1 BRCA1 associated RING domain1 3.34E-06 - 
AKT1 v-akt murine thyoma viral oncogene 3.34E-06 - 
RB1CC1 RB1-inducible  coiled-coil 1 6.68E-06 - 
KRAS 
v-Ki-ras2 Kirsten rat  
sarcoma viral oncogene 4.21E-03 0.0126 
 
Table 4. Breast cancer genes that were found to have a significant relationship with the 
collection of factors that are exclusive to each breast cancer cell line.  
 
Figure 13. The role of PPM1D (highlighted in red as Wip1) in the p53 negative feedback pathway 
(http://www.genome.jp/kegg-bin/highlight_pathway). 
 
between the MDA-MB-231 or MCF7 genes and the breast cancer gene set is given a p value, with a value 
of 0 indicating the most significant relationship. The most compelling gene relationships are presented 
in Table 4.  
  
        One of 
the most 
noteworthy 
links 
presented in 
both breast 
cancer cell 
types is with 
the PPM1D 
gene  (also 
known as 
Wip1), which encodes a protein that is a part of the PPM family of Ser/Thr phosphatases. This family is 
known to negatively regulate cell stress response pathways, including the p53 signaling pathway. The 
activation of p53 by DNA damage induces PPM1D. Selective inactivation of the p38 MAP kinase by 
PPM1D leads to suppression of p53 and negative regulation of subsequent tumor suppressor pathways. 
In many different cancers, including 11-16% of primary breast cancers, PPM1D is known to be amplified 
(Rayter, 2008). Other functions of PPM1D that may contribute to its oncogenic effects include regulation 
of the progesterone receptor, base excision pathway of DNA repair, and activation of ATM (ataxia-
telangiectasia mutated). These factors in conjunction with the data gathered from the MDA-MB-231 and 
MCF7 samples suggest that PPM1D and/or associated factors could be a potential therapeutic target. 
The integral role that PPM1D plays specifically in the p53 pathway alludes to is likely importance in 
cancer growth and regulation in MDA-MB-231 and MCF7 cells. 
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 Other important genes to note in Table 4 include BRCA1 (breast cancer 1, early onset), which is 
expressed in breast tissue cells, and helps repair damaged DNA or destroy cells if the DNA cannot be 
repaired. Abnormal BRCA1 greatly increases risk of breast cancer. Also, TSG101 may play a role in cell 
differentiation and acts as a negative growth regulator; it has been found to be frequently mutated in 
breast cancers. KRAS is a proto-oncogene that acts as a molecular switch in the Ras pathway. Although 
these genes are not directly integrated within the p53 pathway, they appear to have a significant impact 
on the molecular networks of the MDA-MB-231 and MCF7 cancer, and could be potential therapeutic 
targets, pending further research and analysis of their specific roles within each breast cancer cell line 
(Kao, 2009). 
 Comparison of MS data reveals that there are more factors exclusive to the MDA-MB-231 cell 
line versus the MCF7 cell line. This may be due to the fact that the first breast cancer cell type is overall 
more aggressive, and genes that are not usually expressed under normal conditions are now up 
regulated. Alternatively, more peptides were identified in the MDA-MB-231 MS analysis. In both MCF7 
and MDA-MB-231 cells, the binding of p53-AD to Mediator induces similar, if not identical 
conformational changes in Mediator, thus revealing the same, previously unexposed protein domains. 
However, the differences between the two breast cancer lines lie in the fact that many more protein 
factors are present in the MDA-MB-231 cell. Different cancers have different gene expression patterns, 
as evidenced by the genes found solely in MCF7 cells versus MDA-MB-231 cells (Jones, 2008). The 
proteins that are exclusive to the MDA-MB-231 cells may be able to bind to the newly revealed domains 
of Mediator and alter global gene expression patterns. By contrast, such factors are absent from MCF7 
cells. Thus, whereas the same Mediator domain becomes exposed upon p53AD binding, a subsequent 
interaction with the cofactor may not occur in MCF7 cells.  
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Future Directions 
 The conditions of glycerol gradient purifications allow larger protein complexes to be left whole 
and intact for analysis. For both MCF7 and MDA-MB-231 cells, the regions of the glycerol gradients 
highlighted as the early fractions show evidence of a diversity of factors within the p53 network. This is 
expected since both breast cancer cell lines express p53. MCF7 cells express wild type p53, while MDA-
MB-231 cells express a hyperactive, mutant p53. In the later fractions of the glycerol gradients, it is 
apparent that some bands become fainter and even disappear as others appear and become darker.  
These changes represent the different protein complexes migrating throughout the gradient. The p53-
Mediator interaction induces conformational shifts that may reveal previously inaccessible binding sites. 
This may stimulate the binding and activation of various co-activators that activate other genes. 
 To characterize the proteins that compose the “p53 network” and p53-Mediator fractions that 
were generated using glycerol gradient purifications, mass spectrometry will be carried out on these 
samples. Analysis of these samples will be similar to the analysis of the MED1 IP samples (Figure 12). 
This will identify additional protein factors that are similar and different between the two breast cancer 
cell lines. Further analysis of the proteins that are differentially represented between the two breast 
cancer cell lines will determine their role in specific gene pathways that may or may not be a part of the 
p53 network and/or Mediator interaction.  These unique factors and potential transcriptional co-
regulators may contribute to the clinical differences between the two cell lines (Sorlie, 2001). Such 
clinical differences include drug resistance, invasiveness and overall aggressiveness. The next step would 
be determining if manipulating the expression of the protein(s) in tissue culture will affect the clinical 
characteristics of the breast cancer, or if the protein is a potential therapeutic target.  
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Experimental Procedures 
 
Protease Inhibitors : 1mM Benzamidine HCl, 1mM Sodium Metabisulfite, 1mM Dithiothreitol 
 
Cell Cultures 
 MCF7: 
 Cells are cultured in Roswell Park Memorial Institute (RPMI) medium with 10% Fetal Bovine 
Serum (FBS) and 10% Penicilin-Streptomycin (Pen-Strep). Cell grow adhered to a surface and are 
incubated at 37°C in 5% carbon dioxide. When splitting cells to a higher passage number, wash cells 
twice with Dulbecco’s Phosphate Buffered Saline (DPBS) and then use 0.05% trypsin to remove adhered 
cells from the surface of the culture plate. 
 MDA-MB-231: 
 Cells are cultured in Leibovit’s L-15 medium with 10% FBS and 10% Pen-Strep. Cells grow 
adhered to a surface and are incubated at 37°C and 0% carbon dioxide. When splitting cells, wash cells 
twice with DPBS and then use 0.25% trypsin to release the adhered cells from the surface of the culture 
plate. 
 
Isolating Cell Nuclei 
For both MCF7 and MDA-MB-231: 
 Remove 90% of the media from the culture plate. Using a plastic cell scraper, scrape cells off of 
the plate and pipet into a 50mL conical tube. Keep cells on ice at all times. Centrifuge tubes at 4000RPM 
and 4°C for 20 minutes. Remove the supernatant and measure the packed cell volume (PCV). Resuspend 
the cell pellet in twice the PCV PBSM (1X phosphate-buffered saline, 0.5% MgCl2) plus protease 
inhibitors.  Spin the cells at 4000RPM and 4°C for 10 minutes. Thoroughly resuspend the cell pellet in 
five times the PCV Buffer A (10X Buffer A: 100 mM HEPES, 15 mM MgCl2, 100 mM KCl, pH=7.9) plus 
protease inhibitors. Spin the cells at 4000RPM and 4°C for 10 minutes. Let the cells sit on ice for 20 
minutes. Spin the cells at 4000RPM and 4°C for 10 minutes.  Remove the supernatant. Resuspend the 
cell pellet in two times PCV Buffer A. Using a type A dounce homogenizer, dounce the cells five times. 
Spin cells at 2800RPM for 10 minutes. At this point, the upper and lower phases should be apparent. 
Remove the cytoplasm upper phase with a pipet. Save the cell nuclei lower phase. Flash freeze the lower 
phase in liquid nitrogen and then store the cell nuclei at -80°C.  
 
Nuclear Extract Preparation 
For both MCF7 and MDA-MB-231: 
 Thaw cell nuclei pellet and then keep on ice. Add 90% nuclei volume of Buffer C (20mM HEPES, 
24% glycerol, 0.4M NaCl, 1.5 mM MgCl2, 0.5M EDTA, pH 7.9) plus protease inhibitors. Using a type B 
glass homogenizer, dounce the nuclear material twenty times. Rock at 4°C for 30 minutes. Spin at 
15000RPM and 4°C for 30 minutes.  Keep the supernatant.  Place dialysis tubing in 1L of Buffer D (20 
mM HEPES, 20% glycerol, 100 mM KCl, 2 mM MgCl2, 0.2 mM EDTA) plus protease inhibitors to 
equilibrate tubing. Then, place supernatant in dialysis tubing and dialyze to 0.1M salt (roughly two 
hours). Aliquot supernatant into 1.5mL tubes. Flash freeze in liquid nitrogen and then store nuclear 
extract at -80°C.  
 
Immunoprecipitation 
For both MCF7 and MDA-MB-231: 
 Combine 40µL of Protein A resin beads and 40µL of Protein G resin beads in a 1mL eppendorf 
tube. Wash beads twice with 0.15M HEGN (20mM HEPES, 5µM EDTA, 10% glycerol, 1mL 10% NP-40, 
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75mM KCl). Spin after each wash at 4000RPM and 4°C for one minute. Remove supernatant. Add 80µL 
of 0.15M HEGN to resin beads. Add 80µL of MED1 antibody. Flick eppendorf to resuspend beads and 
then rock at 4°C for 90 minutes. While tube is rocking, thaw 1mL of nuclear extract and then spin at 
14000RPM and 4°C for 20 minutes. Keep nuclear extract supernatant.  When eppendorf tube with beads 
and antibody is finished rocking, spin at 4000RPM and 4°C for one minute. Wash beads three times with 
1mL of 0.5M HEGN plus protease inhibitors. Then wash beads once with 0.15M HEGN plus protease 
inhibitors. Spin between each wash at 4000RPM and 4°C for one minute. After washes are complete, 
add the 1mL of nuclear to the A/G resin beads. Rock at 4°C for three hours.  After rocking, spin at 
4000RPM and 4°C for one minute. Wash beads five times with 1mL of 0.5M HEGN. Then wash beads 
once with 1mL 0.15M HEGN. Spin beads between each wash at 4000RPM and 4°C for one minute. Make 
elution buffer by combing 800µL 0.15M HEGN and 200µL of 10% sarkosyl. Remove supernatant from 
beads after last wash and then add 80µL of elution buffer to the beads. Rock at 4°C for 30 minutes. After 
rocking, spin at 4000RPM and 4°C for one minute. Pipet off 70µL of supernatant and place into a filter 
tube. Spin filter tube at 4000RPM and 4°C for one minute. Add another 80µL of elution buffer to the 
tube with the A/G resin beads. Rock for another 30 minutes at 4°C. Spin tube at 4000RPM and 4°C for 
one minute. Pipet off all of the eluted material and place into the original filter tube. Spin filter tube at 
4000RPM and 4°C for two minutes. To prepare samples to be run on the gel, add 10µL of 2X loading 
buffer to 10µL of the eluted material. Load 12µL in the gel. To the beads, add 10µL of 2X loading buffer. 
Load 3µL into the gel.  
 
Silver Stain 
 Shake gel in 50% methanol for 10 minutes, 5% methanol for 10 minutes, 3.5µM DTT for 5 
minutes and silver nitrate solution (250mg silver nitrate, 25µL formaldehyde in 250mL of water) for 10 
minutes. Wash the gel twice with cold water. Then wash the gel twice with developing solution (15g 
sodium carbonate, 250µL formaldehyde in 500mL of water). Shake gel in developing solution until the 
desired intensity is reached. Quench with citric acid monohydrate until neutral pH. Transfer gel to water.  
 
Growth/Expression of GST-p53 protein 
 Day 1: Take 20µL of BL21 E. coli cells with the p53 codon and add to 1mL of luria broth (LB) in a 
1mL eppendorf tube. Shake at 37°C for one hour. Prepare an ampicilin agar plate. Prepare LB by placing 
a LB dry pellet in a 2.8L flask with 1L of mili-Q water. Autoclave for 45 minutes. After cells are finished 
rocking, place 3µL onto the ampicilin placte. Keep plate upside down and incubate at 37°C overnight. 
 Day2: Pick a single colony (large and isolated from other colonies) with a 10µL filter tip and add 
it to 5mL of LB in a culture tube. Let the culture grow by rocking at 37°C overnight. 
 Day 3: Prepare ampicilin by adding 100mg ampicilin to 1mL of water. Add this to the 1L of 
autoclaved LB. Add 3mL of the overnight culture to the LB. Shake the 1L culture at 37°C. Let the culture 
grow until the OD600=0.6-0.8 (about 3-4 hours). When the OD600 reads the optimal absorbance value, 
reduce the temperature to 30°C and induce expression with 0.4mM IPTG (Isopropyl-β-D-
thiogalactoside). Shake at 30°C for another 4 hours.  Spin the cells at 4000RPM and 4°C for 10 minutes. 
Pour off supernatant into a container with bleach. Keep the cells on ice. Resuspend the cell pellet in cold 
1X PBS (phosphate-buffered saline) plus protease inhibitors (45mL 1XPBS/500mL of cells). Spin 
resuspended cells at 2750RPM and 4°C for 10 minutes. Remove supernatant. Flash freeze the pellet in 
liquid nitrogen and store at -80°C.  
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Figure 14. Work up of GST-p53AD. 
expression. 
 
GST-p53 Purification/GSH-Sepharose Immobilization 
 Thaw the cell pellet and then keep on ice. Resuspend the 
thawed cell pellet in H/E buffer (50mM Tris, 0.5M NaCl, 5µM 
EDTA, 10% glycerol, 25mL 10% NP-40)  plus protease inhibitors 
(5mL H/E /250mL cells). Lyse cells by sonicating three times for 30 
seconds, with one minute breaks in between.  Centrifuge lysate at 
4000RPM and 4°C for 30 minutes. While lysate is spinning, prepare 
GSH-Sepharose beads. In a 15mL conical tube, add 150µL of 
glutathione beads (300µL of the bead slurry). Add 5mL of H/E to 
the beads and spin at 2000RPM and 4°C for 5 minutes. Remove 
buffer from the beads. When lysate is finished spinning, pour 
supernatant over the GSH-Sepharose beads. Rock the beads at 4°C 
for one hour. Then spin beads at 2500RPM and 4°C for 5 minutes.  
Remove supernatant. Wash beads five times with 5mL each time 
of High Salt buffer plus protease inhibitors (1M NaCl, 50mM Tris, 
5μM EDTA, 10% glycerol by volume, 50mL 10% NP-40 NP-40, 8mM 
CHAPS). Then wash beads two times with 5mL each of H/E plus 
protease inhibitors. Finally, wash once with 5mL of 0.15M HEGN. Spin between each wash at 2000RPM 
and 4°C for one minute. After last wash, remove most of the buffer, leaving ~250µL covering the beads. 
Store beads at 4°C for a maximum of seven days.  
 
Nuclear Extract Pull-down 
For both MCF7 and MDA-MB-231: 
 Thaw 1mL of nuclear extract and then spin at 15000RPM and 4°C for 25 minutes. On ice, pipet 
100µL of GST-p53 immobilized beads into a 1.5mL tube. Spin beads at 2000RPM and 4°C for five 
minutes. Remove the supernatant buffer on top of the beads. After nuclear extract is finished spinning, 
add the supernatant to the beads. Rock overnight at 4°C. Spin tube at 2000RPM and 4°C for two 
minutes. Was five times with 1mL each of 0.5M HEGN plus protease inhibitors. Then wash once with 
1mL of 0.15M HEGN. Spin in between each wash at 2000RPM and 4°C for one minute. Remove 
supernatant from beads. Elute with bead volume of 30mM GSH in Tris Elution buffer (0.15M salt). Rock 
at 4°C for 30 minutes. Then spin at 2200RPM and 4°C for five minutes. Pipet off supernatant into a 
microfilter tube. Spin microfilter tube at 6000RPM and 4°C for three minutes. Add an additional bead 
volume of elution buffer to the beads. Rock again at 4°C for 30 minutes. Spin again at 2200RPM and 4°C 
for two minutes. Place supernatant into the original microfilter tube. Spin microfilter tube again at 
6000RPM and 4°C for three minutes. To prepare a gel sample, add 5µL of eluted material to 5µL of 2X 
loading buffer. Load 9µL into the gel.  
 
Glycerol Gradient 
 Pour a 15%-40% glycerol gradient into 2mL Beckman Centrifuge Tubes. Very carefully, transfer 
the eluted material from nuclear extract pull-down to the top of the gradient in the tube. Spin tubes at 
55000RPM and 4°C for 6 hours. Pipet off 100µL fractions. To prepare gel samples, add 5µL 4X loading 
buffer to 10µL of the gradient fraction sample. Load 13µL.  
Mass Spectrometry 
 All mass spectrometry work was done by Chris Ebmeier. The specific protocol can be found in 
the methods sections of “Molecular Architecture of the Human Mediator – RNA Polymerase II – TFIIF 
Assembly” by Carrie Bernecky et al. in PLoS Biology 9(3), 1-18. 
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Gene 
MDA-MB-231 
Spectral Counts 
MCF7 
Spectral Counts MW (Da) 
 
Gene 
MDA-MB-2313 
Spectral Counts 
MCF7 
Spectral Counts MW (Da) 
VIM 156 0 53652 
 
HNRNPL 14 0 64133 
FLNC 98 0 291022 
 
PLIN3 14 0 45803 
AKAP2 35 0 122071 
 
SMN1 14 0 31849 
AP2B1 30 0 104553 
 
TRIP11 14 0 227639 
TPM3 28 0 28922 
 
EIF4G1 13 0 175619 
DHX15 27 0 90933 
 
MYO1B 13 0 
 DST 26 0 633667 
 
PPP1R12C 13 0 84881 
HIP1R 26 0 119388 
 
RBM39 13 0 59380 
CKAP5 25 0 225495 
 
RBM8A 13 0 19889 
CALD1 24 0 93250 
 
ATP2A2 12 0 109691 
SNRPD2 23 0 13527 
 
CDC42BPB 12 0 194315 
RP11-
631M21.2 21 0 
  
CPSF6 12 0 59210 
SFRS1 20 0 27745 
 
RAD50 12 0 138432 
SFRS2 20 0 25476 
 
SNRPE 12 0 10804 
TPM1 19 0 
  
SQSTM1 12 0 47687 
IMPDH2 18 0 55805 
 
TLN1 12 0 269767 
RPL18 18 0 21634 
 
DDX23 11 0 95583 
UHRF1 18 0 91100 
 
LRPPRC 11 0 157905 
EHD1 17 0 60627 
 
LYAR 11 0 43615 
LUZP1 17 0 120275 
 
RAI14 11 0 110423 
RPL4 17 0 47697 
 
SERPINH1 11 0 46441 
AP2A1 16 0 105370 
 
STAMBPL1 11 0 52199 
LEPRE1 16 0 90616 
 
HSP90AB1 10 0 
 MYLK 16 0 203128 
 
NEXN 10 0 80658 
THOC4 16 0 27558 
 
RPL3 10 0 46109 
AP2M1 15 0 49655 
 
RPL32 10 0 15860 
KRT7 15 0 51418 
 
RPS2 10 0 31324 
MYL9 15 0 13866 
 
SKIV2L2 10 0 117805 
RPL14 15 0 23787 
 
SRRM2 10 0 299615 
TOP2A 15 0 183124 
 
U2AF1 10 0 27872 
ANXA1 14 0 38714 
      
Appendix A. Factors receiving a spectral count of 10 and above found only in the MDA-MB-231 breast cancer cell line. 
Appendix  
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Appendix B. Factors receiving a spectral count of 10 and above found exclusively in MCF7 cells. 
Gene Protein description 
MDA-MB-23l 
Spectral Counts 
MCF7 
Spectral Counts MW (Da) 
SPTBN2 SPECTRIN BETA CHAIN, BRAIN 2 0 39 271295 
EPPK1 EPIPLAKIN 1 0 22 555621 
SYTL2 SYNAPTOTAGMIN-LIKE PROTEIN 2 0 16 197919 
MYO5B MYOSIN-VB 0 14 213756 
CGN CINGULIN 0 13 137057 
FAM83H Family with sequence similarity 83, member H 0 13 127101 
LAD1 LADININ-1 0 11 57131 
MYO1D MYOSIN-ID 0 10 116202 
Septin8 PROTEIN SEPT8 0 10 50928 
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